Electrochemotherapy

Last updated
Electrochemotherapy
Specialty oncology

Electrochemotherapy (ECT [1] ) is a type of chemotherapy that allows delivery of non-permeant drugs to the cell interior. It is based on the local application of short and intense electric pulses that transiently permeabilize the cell membrane, thus allowing transport of molecules otherwise not permitted by the membrane. [2] [3] Applications for treatment of cutaneous and subcutaneous tumors have reached clinical use by utilizing drugs such as bleomycin or cisplatin). [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] Electrochemotherapy with bleomycin was used to treat a patient for the first time in 1991 at the Institute Gustave Roussy in France, [14] while electrochemotherapy with cisplatin was used to treat for the first time in 1995 at the Institute of Oncology, Ljubljana, Slovenia. [15] Since then, more than 4000 patients were treated with electrochemotherapy all over the world (Argentina, Australia, Austria, Belgium, Bulgaria, Denmark, France, Germany, Greece, Hungary, Ireland, Italy, Japan, Mexico, Nicaragua, Poland, Portugal, Slovenia, Spain, Sweden, UK, USA). Recently, new electrochemotherapy modalities have been developed for treatment of internal tumors using surgical procedures, endoscopic routes, or percutaneous approaches to gain access to the treatment area. [16] [17]

Contents

Physical principle

Basic steps in electrochemotherapy treatment Shema ect.jpg
Basic steps in electrochemotherapy treatment

When a biological cell is exposed to an electric field of sufficient strength, an increase in the transmembrane voltage is generated, which leads to rearrangements of the cell membrane structure. [18] [19] [20] [21] [22] [23] These changes result in an increase of the cell membrane permeability, which allows nonpermeant molecules to enter the cell. [14] [24] [25] This phenomenon is called electroporation (or electropermeabilization) and is becoming widely used to improve anticancer drug delivery into cells, which is being referred to as electrochemotherapy.

All biomedical applications of cell electropermeabilization use direct currents (all unipolar) with short and intense pulses (even though in vitro, time-decayed pulses can be used). Amplitude of the pulses depends on the tissues and on the shape and position of the electrodes, but, in vivo, in the case of the tumors, the amplitude of the electric pulses has to be high enough to establish an electrical field of 400 V/cm in the area of tumor (8 pulses with duration of 100 microseconds). [26] The duration of pulses is usually one hundred microseconds. In early experiments, pulses were delivered with period of 1 second (i.e. at a repetition frequency of 1 Hz); today, pulses are delivered in a much shorter time period, at a repetition frequency of 5000 Hz, resulting in a much less discomfort for the patient and in the shorter duration of treatment. [27] [28] For treatment of deep-seated tumors in relative vicinity of the heart, pulses are synchronized with absolute refractory period of each heartbeat to minimize the probability of interaction of pulses with the heart function. [29] [30]

Treatment

Left: plate electrodes; Right: needle electrodes Electrodes ect.jpg
Left: plate electrodes; Right: needle electrodes

The electrochemotherapeutic treatment consists of delivering, either systemically or locally, non-permeant cytotoxic drugs (e.g. bleomycin) or low-permeant drugs (e.g. cisplatin) and applying electric pulses to the area to be treated when the concentration of the drug in the tumor is at its peak. [13] With the delivery of the electric pulses, cells are subjected to an electric field that causes the formation of nanoscale defects on the cell membrane, which alter the permeability of the membrane. At this stage and for some time after pulses are delivered, molecules of the cytotoxic agents can freely diffuse into the cytoplasm and exert their cytotoxic effect. Multiple positioning of the electrodes, and subsequent pulse delivery, can be performed during a session to treat the whole lesion, provided that drug concentration is sufficient. [26] Treatment can be repeated over the course of weeks or months to achieve regression of large lesions.

Efficacy and clinical relevance

In a number of clinical studies (phase II and phase III), investigators have concluded that electrochemotherapy of cutaneous or subcutaneous metastasis or tumours with bleomycin and cisplatin have an objective response rate of more than 80%. [31] Reduction of tumor size has been achieved with electrochemotherapy faster and more efficiently than in standard chemotherapy for both cutaneous and subcutaneous tumors. Patients with skin metastasis from melanoma, Kaposi sarcoma, squamous cell carcinoma, basal cell carcinoma, adenocarcinoma, or breast cancer have been successfully treated. [5] [6] [7] [8] [10] [11] [32] First clinical results of electrochemotherapy of internal tumors (e.g. liver metastases) are also promising and encouraging. The success rate for electrochemotherapy in "human malignancies" has been stated to be more than 80% provided that a proper patient selection criteria will be performed.

Safety

Electrochemotherapy employs lower dosages of chemotherapeutic drugs than standard chemotherapy protocols; thus, the patient's burden usually associated to chemotherapy is not present. In the clinical use of electrochemotherapy, limited side effects related to bleomycin or cisplatin use are recorded. Provided that appropriate anesthesia is used for alleviation of the symptoms associated with application of electric pulses, the control of the pain level during the electrochemotherapy is acceptable for the patients. Other than pain, which is limited to the treated tumor and surrounding tissue, muscle contraction during electric pulse delivery is the only other discomfort. [5] There is also induction of a vascular lock by the type of pulses used in electrochemotherapy: for a few minutes, blood flow is interrupted in the treated volume in the normal tissues. [33] [34] Its duration is too short to induce deleterious effects due to ischemia. In tumors however, vascular lock is of a longer duration and can contribute to the effectiveness of the electrochemotherapy.

Veterinary use

Electrochemotherapy is also used in veterinary oncology for a variety of tumors in dogs, cats, horses, and rabbits. There are centers in Argentina, Brazil, [35] [36] Chile, Uruguay, Paraguay, Mexico, Peru, Bolivia, Colombia, Ecuador, Republica Dominicana, Spain, France, Italy, Ireland, Slovenia, United Arab Emirates, and the UK,. [37] There are now multiple institutions in the US including Maine, New York, Rhode Island, Washington, Missouri, South Carolina, Hawaii, Las Vegas, Florida, Virginia, and the Bay Area of Northern California where this treatment is available.

The success rate for electrochemotherapy has been stated to be around 90%, with an average of 3-4 treatments in the case of rabbits.

See also

Related Research Articles

<span class="mw-page-title-main">Chemotherapy</span> Treatment of cancer using drugs that inhibit cell division or kill cells

Chemotherapy is a type of cancer treatment that uses one or more anti-cancer drugs as part of a standardized chemotherapy regimen. Chemotherapy may be given with a curative intent or it may aim to prolong life or to reduce symptoms. Chemotherapy is one of the major categories of the medical discipline specifically devoted to pharmacotherapy for cancer, which is called medical oncology.

<span class="mw-page-title-main">Electroporation</span> Method in molecular biology to make pores in cell membranes

Electroporation, or electropermeabilization, is a technique in which an electrical field is applied to cells in order to increase the permeability of the cell membrane. This may allow chemicals, drugs, electrode arrays or DNA to be introduced into the cell.

<span class="mw-page-title-main">Bladder cancer</span> Urinary system cancer that begins in the urinary bladder

Bladder cancer is any of several types of cancer arising from the tissues of the urinary bladder. Symptoms include blood in the urine, pain with urination, and low back pain. It is caused when epithelial cells that line the bladder become malignant.

<span class="mw-page-title-main">Testicular cancer</span> Medical condition

Testicular cancer is cancer that develops in the testicles, a part of the male reproductive system. Symptoms may include a lump in the testicle or swelling or pain in the scrotum. Treatment may result in infertility.

<span class="mw-page-title-main">Renal cell carcinoma</span> Medical condition

Renal cell carcinoma (RCC) is a kidney cancer that originates in the lining of the proximal convoluted tubule, a part of the very small tubes in the kidney that transport primary urine. RCC is the most common type of kidney cancer in adults, responsible for approximately 90–95% of cases. RCC occurrence shows a male predominance over women with a ratio of 1.5:1. RCC most commonly occurs between 6th and 7th decade of life.

<span class="mw-page-title-main">Germ cell tumor</span> Medical condition

Germ cell tumor (GCT) is a neoplasm derived from the primordial germ cells. Germ-cell tumors can be cancerous or benign. Germ cells normally occur inside the gonads. GCTs that originate outside the gonads may be birth defects resulting from errors during development of the embryo.

<span class="mw-page-title-main">Pemetrexed</span> Chemical compound

Pemetrexed, sold under the brand name Alimta among others, is a chemotherapy medication for the treatment of pleural mesothelioma and non-small cell lung cancer (NSCLC)..

<span class="mw-page-title-main">Cancer immunotherapy</span> Artificial stimulation of the immune system to treat cancer

Cancer immunotherapy (immuno-oncotherapy) is the stimulation of the immune system to treat cancer, improving on the immune system's natural ability to fight the disease. It is an application of the fundamental research of cancer immunology and a growing subspecialty of oncology.

<span class="mw-page-title-main">Sclerotherapy</span> Shrinking of the varicose blood vessels by the injection of medicine

Sclerotherapy is a procedure used to treat blood vessel malformations and also malformations of the lymphatic system. A medicine is injected into the vessels, which makes them shrink. It is used for children and young adults with vascular or lymphatic malformations. In adults, sclerotherapy is often used to treat spider veins, smaller varicose veins, hemorrhoids, and hydroceles.

<span class="mw-page-title-main">Non-small-cell lung cancer</span> Any type of epithelial lung cancer other than small-cell lung carcinoma

Non-small-cell lung cancer (NSCLC), or non-small-cell lung carcinoma, is any type of epithelial lung cancer other than small-cell lung cancer (SCLC). NSCLC accounts for about 85% of all lung cancers. As a class, NSCLCs are relatively insensitive to chemotherapy, compared to small-cell carcinoma. When possible, they are primarily treated by surgical resection with curative intent, although chemotherapy has been used increasingly both preoperatively and postoperatively.

<span class="mw-page-title-main">Salivary gland tumour</span> Medical condition

Salivary gland tumours, also known as mucous gland adenomas or neoplasms, are tumours that form in the tissues of salivary glands. The salivary glands are classified as major or minor. The major salivary glands consist of the parotid, submandibular, and sublingual glands. The minor salivary glands consist of 800 to 1000 small mucus-secreting glands located throughout the lining of the oral cavity. Patients with these types of tumours may be asymptomatic.

Vaccine therapy is a type of treatment that uses a substance or group of substances to stimulate the immune system to destroy a tumor or infectious microorganisms such as bacteria or viruses.

<span class="mw-page-title-main">HPV-positive oropharyngeal cancer</span> Cancer of the throat

Human papillomavirus-positive oropharyngeal cancer, is a cancer of the throat caused by the human papillomavirus type 16 virus (HPV16). In the past, cancer of the oropharynx (throat) was associated with the use of alcohol or tobacco or both, but the majority of cases are now associated with the HPV virus, acquired by having oral contact with the genitals of a person who has a genital HPV infection. Risk factors include having a large number of sexual partners, a history of oral-genital sex or anal–oral sex, having a female partner with a history of either an abnormal Pap smear or cervical dysplasia, having chronic periodontitis, and, among men, younger age at first intercourse and a history of genital warts. HPV-positive OPC is considered a separate disease from HPV-negative oropharyngeal cancer.

Lipoplatin is a nanoparticle of 110 nm average diameter composed of lipids and cisplatin. This new drug has successfully finished Phase I, Phase II, and Phase III human clinical trials. It has shown superiority to cisplatin in combination with paclitaxel as a chemotherapy regimen in non-small cell lung cancer (NSCLC) adenocarcinomas.

Irreversible electroporation is a soft tissue ablation technique using short but strong electrical fields to create permanent and hence lethal nanopores in the cell membrane, to disrupt cellular homeostasis. The resulting cell death results from induced apoptosis or necrosis induced by either membrane disruption or secondary breakdown of the membrane due to transmembrane transfer of electrolytes and adenosine triphosphate. The main use of IRE lies in tumor ablation in regions where precision and conservation of the extracellular matrix, blood flow and nerves are of importance. The first generation of IRE for clinical use, in the form of the NanoKnife System, became commercially available for research purposes in 2009, solely for the surgical ablation of soft tissue tumors. Cancerous tissue ablation via IRE appears to show significant cancer specific immunological responses which are currently being evaluated alone and in combination with cancer immunotherapy.

Interventional oncology is a subspecialty field of interventional radiology that deals with the diagnosis and treatment of cancer and cancer-related problems using targeted minimally invasive procedures performed under image guidance. Interventional oncology has developed to a separate pillar of modern oncology and it employs X-ray, ultrasound, computed tomography (CT) or magnetic resonance imaging (MRI) to help guide miniaturized instruments to allow targeted and precise treatment of solid tumours located in various organs of the human body, including but not limited to the liver, kidneys, lungs, and bones. Interventional oncology treatments are routinely carried out by interventional radiologists in appropriate settings and facilities.

This is a historical timeline of the development and progress of cancer treatments, which includes time of discovery, progress, and approval of the treatments.

<span class="mw-page-title-main">Extracranial germ cell tumor</span> Type of tumor

An extracranial germ cell tumor (EGCT) occurs in the abnormal growth of germ cells in the gonads and the areas other than the brain via tissue, lymphatic system, or circulatory system. The tumor can be benign or malignant (cancerous) by its growth rate. According to the National Cancer Institute and St. Jude Children's Research Hospital, the chance of children who are under 15 years old having EGCTs is 3%, in comparison to adolescents, a possibility of 14% with aged 15 to 19 can have EGCTs. There is no obvious cut point in between children and adolescents. However, common cut points in researches are 11 years old and 15 years old.

Ovarian germ cell tumors (OGCTs) are heterogeneous tumors that are derived from the primitive germ cells of the embryonic gonad, which accounts for about 2.6% of all ovarian malignancies. There are four main types of OGCTs, namely dysgerminomas, yolk sac tumor, teratoma, and choriocarcinoma.

<span class="mw-page-title-main">Limited-stage small cell lung carcinoma</span> Medical condition

Limited-stage small cell lung carcinoma (LS-SCLC) is a type of small cell lung cancer (SCLC) that is confined to an area which is small enough to be encompassed within a radiation portal. This generally includes cancer to one side of the lung and those might have reached the lymph nodes on the same side of the lung. 33% patients with small cell lung cancer are diagnosed with limited-stage small cell lung carcinoma when it is first found. Common symptoms include but are not limited to persistent cough, chest pain, rust-coloured sputum, shortness of breath, fatigue, weight loss, wheezing, hoarseness and recurrent respiratory tract infections such as pneumonia and bronchitis. Nervous system problems, Cushing syndrome and SIADH can also be associated with small cell lung cancer. Unlike extensive-stage small cell lung cancer, limited-stage small cell lung carcinoma is potentially curable. Standard treatments consist of surgery, platinum-based combination chemotherapy, thoracic irradiation, and prophylactic cranial irradiation. Patient five-year survival rate has significantly increased from 1% with surgery to 26% after the application of combination chemotherapy.

References

  1. ↑ McCall, Becky (28 June 2023). "Under-Recognised Treatment Praised in Skin Tumour Study". Medscape UK.
  2. ↑ Mir LM, Orlowski S, Belehradek J, Paoletti C (1991). "Electrochemotherapy potentiation of antitumour effect of bleomycin by local electric pulses". European Journal of Cancer. 27 (1): 68–72. doi:10.1016/0277-5379(91)90064-k. PMID   1707289.
  3. ↑ Sersa G, Cemazar M, Miklavcic D (August 1995). "Antitumor effectiveness of electrochemotherapy with cis-diamminedichloroplatinum(II) in mice" (PDF). Cancer Research. 55 (15): 3450–5. PMID   7614485.
  4. ↑ Gehl, Julie; Geertsen, Poul F. (November 2006). "Palliation of haemorrhaging and ulcerated cutaneous tumours using electrochemotherapy". European Journal of Cancer. 4 (11): 35–7. doi:10.1016/j.ejcsup.2006.07.007.
  5. 1 2 3 Marty, Michel; Sersa, Gregor; Garbay, Jean Rémi; Gehl, Julie; Collins, Christopher G.; Snoj, Marko; Billard, Valérie; Geertsen, Poul F.; Larkin, John O.; Miklavcic, Damijan; Pavlovic, Ivan; Paulin-Kosir, Snezna M.; Cemazar, Maja; Morsli, Nassim; Soden, Declan M.; Rudolf, Zvonimir; Robert, Caroline; O’Sullivan, Gerald C.; Mir, Lluis M. (November 2006). "Electrochemotherapy – An easy, highly effective and safe treatment of cutaneous and subcutaneous metastases: Results of ESOPE (European Standard Operating Procedures of Electrochemotherapy) study". European Journal of Cancer Supplements. 4 (11): 3–13. doi:10.1016/j.ejcsup.2006.08.002.
  6. 1 2 Larkin JO, Collins CG, Aarons S, et al. (March 2007). "Electrochemotherapy: aspects of preclinical development and early clinical experience". Ann. Surg. 245 (3): 469–79. doi:10.1097/01.sla.0000250419.36053.33. PMC   1877027 . PMID   17435555.
  7. 1 2 Sersa G, Miklavcic D, Cemazar M, Rudolf Z, Pucihar G, Snoj M (February 2008). "Electrochemotherapy in treatment of tumours". Eur J Surg Oncol. 34 (2): 232–40. CiteSeerX   10.1.1.148.9258 . doi:10.1016/j.ejso.2007.05.016. PMID   17614247.
  8. 1 2 Möller MG, Salwa S, Soden DM, O'Sullivan GC (November 2009). "Electrochemotherapy as an adjunct or alternative to other treatments for unresectable or in-transit melanoma". Expert Rev Anticancer Ther. 9 (11): 1611–30. doi:10.1586/era.09.129. PMID   19895245. S2CID   1630835.
  9. ↑ Campana, L. G.; Pasquali, S.; Basso, M.; Mocellin, S.; Vecchiato, A.; Sileni, V. Chiarion; Corti, L.; Nitti, D.; et al. (2010). "Electrochemotherapy: clinical outcome and predictive factors from a single institution experience on 50 melanoma patients". Annals of Surgical Oncology. Vol. 17. Springer. pp. S106.
  10. 1 2 Testori A, Tosti G, Martinoli C, et al. (2010). "Electrochemotherapy for cutaneous and subcutaneous tumor lesions: a novel therapeutic approach". Dermatol Ther. 23 (6): 651–61. doi:10.1111/j.1529-8019.2010.01370.x. PMID   21054709. S2CID   46534637.
  11. 1 2 Hampton T (February 2011). "Electric pulses help with chemotherapy, may open new paths for other agents". JAMA. 305 (6): 549–51. doi:10.1001/jama.2011.92. PMID   21304073.
  12. ↑ Muñoz Madero V, Ortega Pérez G (January 2011). "Electrochemotherapy for treatment of skin and soft tissue tumours. Update and definition of its role in multimodal therapy". Clin Transl Oncol. 13 (1): 18–24. doi:10.1007/s12094-011-0612-2. PMID   21239351.
  13. 1 2 Sersa G, Miklavcic D (2008). "Electrochemotherapy of tumours". J Vis Exp (22). doi:10.3791/1038. PMC   2762922 . PMID   19229171.
  14. 1 2 Mir LM, Belehradek M, Domenge C, et al. (1991). "[Electrochemotherapy, a new antitumor treatment: first clinical trial]". Comptes Rendus de l'Académie des Sciences, Série III (in French). 313 (13): 613–8. PMID   1723647.
  15. ↑ Rudolf, Zvonimir; Stabuc, Borut; Cemazar, Maja; Miklavcic, Damijan; Vodovnik, Lojze; Sersa, G. (1995). "Electrochemotherapy with bleomycin. The first clinical experience in malignant melanoma patients". Radiol Oncol. 29 (6).
  16. ↑ Soden DM, Larkin JO, Collins CG, et al. (February 2006). "Successful application of targeted electrochemotherapy using novel flexible electrodes and low dose bleomycin to solid tumours". Cancer Lett. 232 (2): 300–10. doi:10.1016/j.canlet.2005.03.057. PMID   15964138.
  17. ↑ Miklavcic, Damijan; Snoj, Marko; Zupanic, Anze; Kos, Bor; Cemazar, Maja; Kropivnik, Mateja; Bracko, Matej; Pecnik, Tjasa; Gadzijev, Eldar; Sersa, Gregor (2010). "Towards treatment planning and treatment of deep-seated solid tumors by electrochemotherapy". BioMedical Engineering OnLine. 9: 10. doi: 10.1186/1475-925X-9-10 . ISSN   1475-925X. PMC   2843684 . PMID   20178589.
  18. ↑ Weaver, James C.; Chizmadzhev, Yu. A. (December 1996). "Theory of electroporation: A review". Bioelectrochemistry and Bioenergetics. 41 (2): 135–160. doi:10.1016/S0302-4598(96)05062-3. ISSN   0302-4598.
  19. ↑ Kotnik, Tadej; Bobanović, Feda; Miklavcˇicˇ, Damijian (August 1997). "Sensitivity of transmembrane voltage induced by applied electric fields—A theoretical analysis". Bioelectrochemistry and Bioenergetics. 43 (2): 285–291. doi:10.1016/S0302-4598(97)00023-8. ISSN   0302-4598.
  20. ↑ Weaver, J.C. (February 2000). "Electroporation of cells and tissues" (PDF). IEEE Transactions on Plasma Science. 28 (1): 24–33. Bibcode:2000ITPS...28...24W. doi:10.1109/27.842820. ISSN   0093-3813.
  21. ↑ Chen C, Smye SW, Robinson MP, Evans JA (March 2006). "Membrane electroporation theories: a review". Med Biol Eng Comput. 44 (1–2): 5–14. doi:10.1007/s11517-005-0020-2. PMID   16929916. S2CID   6039291.
  22. ↑ Puc M, Kotnik T, Mir LM, Miklavcic D (August 2003). "Quantitative model of small molecules uptake after in vitro cell electropermeabilization". Bioelectrochemistry. 60 (1–2): 1–10. doi:10.1016/S1567-5394(03)00021-5. PMID   12893304.
  23. ↑ Puc M, Corovi S, Flisar K, Petkovsek M, Nastran J, Miklavcic D (September 2004). "Techniques of signal generation required for electropermeabilization. Survey of electropermeabilization devices". Bioelectrochemistry. 64 (2): 113–24. doi:10.1016/j.bioelechem.2004.04.001. PMID   15296784.
  24. ↑ Cemazar M, Sersa G (December 2007). "Electrotransfer of therapeutic molecules into tissues". Curr. Opin. Mol. Ther. 9 (6): 554–62. PMID   18041666.
  25. ↑ Sersa G, Stabuc B, Cemazar M, Jancar B, Miklavcic D, Rudolf Z (July 1998). "Electrochemotherapy with cisplatin: potentiation of local cisplatin antitumour effectiveness by application of electric pulses in cancer patients". Eur. J. Cancer. 34 (8): 1213–8. doi:10.1016/s0959-8049(98)00025-2. PMID   9849482.
  26. 1 2 Županič, Anže; Čorović, Selma; Miklavčič, Damijan (1 June 2008). "Optimization of electrode position and electric pulse amplitude in electrochemotherapy". Radiology and Oncology. 42 (2): 93–101. doi: 10.2478/v10019-008-0005-5 .
  27. ↑ Pucihar G, Mir LM, Miklavcic D (September 2002). "The effect of pulse repetition frequency on the uptake into electropermeabilized cells in vitro with possible applications in electrochemotherapy". Bioelectrochemistry. 57 (2): 167–72. CiteSeerX   10.1.1.15.1614 . doi:10.1016/S1567-5394(02)00116-0. PMID   12160614.
  28. ↑ Zupanic A, Ribaric S, Miklavcic D (2007). "Increasing the repetition frequency of electric pulse delivery reduces unpleasant sensations that occur in electrochemotherapy" (PDF). Neoplasma. 54 (3): 246–50. PMID   17447858.
  29. ↑ Mali B, Jarm T, Corovic S, et al. (August 2008). "The effect of electroporation pulses on functioning of the heart". Med Biol Eng Comput. 46 (8): 745–57. doi:10.1007/s11517-008-0346-7. PMC   2491703 . PMID   18415132.
  30. ↑ Institute of Oncology Ljubljana (9 November 2020). "Treatment of Liver Metastases With Electrochemotherapy". ClinicalTrials.gov.
  31. ↑ Sersa, Gregor (2006). "The state-of-the-art of electrochemotherapy before the ESOPE study; advantages and clinical uses". European Journal of Cancer Supplements. 4 (11): 52–59. doi:10.1016/j.ejcsup.2006.08.007.
  32. ↑ Heller R, Gilbert R, Jaroszeski MJ (January 1999). "Clinical applications of electrochemotherapy". Adv. Drug Deliv. Rev. 35 (1): 119–129. doi:10.1016/S0169-409X(98)00067-2. PMID   10837693.
  33. ↑ Sersa G, Jarm T, Kotnik T, et al. (January 2008). "Vascular disrupting action of electroporation and electrochemotherapy with bleomycin in murine sarcoma". Br. J. Cancer. 98 (2): 388–98. doi:10.1038/sj.bjc.6604168. PMC   2361464 . PMID   18182988.
  34. ↑ Jarm T, Cemazar M, Miklavcic D, Sersa G (May 2010). "Antivascular effects of electrochemotherapy: implications in treatment of bleeding metastases". Expert Rev Anticancer Ther. 10 (5): 729–46. doi:10.1586/era.10.43. PMID   20470005. S2CID   7626902.
  35. ↑ Suzuki, Daniela O.H.; Anselmo, Jânio; de Oliveira, Krishna D.; Freytag, Jennifer O.; Rangel, Marcelo M.M.; Marques, Jefferson L.B.; Ramos, Airton (February 2015). "Numerical Model of Dog Mast Cell Tumor Treated by Electrochemotherapy: Thoughts and Progress". Artificial Organs. 39 (2): 192–197. doi:10.1111/aor.12333. PMID   25041415.
  36. ↑ Suzuki, Daniela O. H.; Berkenbrock, José A.; Frederico, Marisa J. S.; Silva, Fátima R. M. B.; Rangel, Marcelo M. M. (March 2018). "Oral Mucosa Model for Electrochemotherapy Treatment of Dog Mouth Cancer: Ex Vivo, In Silico, and In Vivo Experiments: ELECTROCHEMOTHERAPY TREATMENT OF DOG MOUTH CANCER". Artificial Organs. 42 (3): 297–304. doi:10.1111/aor.13003. PMID   29027689. S2CID   3722621.
  37. ↑ Cemazar M, Tamzali Y, Sersa G, et al. (2008). "Electrochemotherapy in veterinary oncology". J. Vet. Intern. Med. 22 (4): 826–31. doi: 10.1111/j.1939-1676.2008.0117.x . PMID   18537879.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.